Company Number: 14554320

Analysis Date: 2025-07-20 12:25 UTC

Financial Health Assessment Report for STONEPHARMA LIMITED

---

1. Financial Health Score: B

Explanation:
STONEPHARMA LIMITED demonstrates solid foundational financial health typical of a young micro-entity business. The company shows improving net current assets and net equity, indicating strengthening liquidity and capital base. However, absolute values remain modest reflecting early-stage status and limited scale, which temper the overall rating.

---

2. Key Vital Signs

Metric	2024 (£)	2023 (£)	Interpretation
Current Assets	34,785	26,018	Growing short-term resources available to meet debts.
Current Liabilities	23,865	22,926	Obligations due within one year; relatively stable.
Net Current Assets (Working Capital)	10,920	3,092	Positive and increasing - healthy short-term financial cushion.
Net Assets (Shareholders Funds)	9,960	2,132	Equity base increasing - business value growing.
Number of Employees	1	1	Small workforce consistent with micro-entity status.

Interpretation:
The company’s working capital (current assets minus current liabilities) is positive and improving, akin to a healthy pulse indicating adequate liquidity to cover short-term debts. The net assets are increasing steadily, showing the business is building its capital foundation. The stability in liabilities suggests no alarming increase in short-term financial obligations.

---

3. Diagnosis

• Liquidity ("Healthy Cash Flow"): The company has positive net current assets, meaning it can comfortably pay its short-term obligations. The increase from £3,092 in 2023 to £10,920 in 2024 is a strong symptom of improving cash management and operational efficiency.

• Solvency ("Strong Backbone"): Shareholders’ funds have risen from £2,132 to £9,960, indicating the company is accumulating retained earnings or capital injections, which strengthen its equity and reduce financial risk.

• Scale and Growth ("Early-stage Vitality"): Being a micro-entity with just one employee, the company is in its infancy but shows encouraging growth in financial resources.

• Risk Factors ("No Symptoms of Distress"): No overdue filings, no directors’ disqualifications, and positive financial trends suggest no current distress signals.

---

4. Recommendations

1. Maintain Liquidity Discipline:
   Continue monitoring working capital closely. As the company grows, maintain a buffer to manage any unforeseen expenses or slow payments.

2. Build Profit Reserves:
   Focus on generating profits and retaining earnings to further strengthen shareholders’ funds, which will act as a financial cushion.

3. Plan for Scaling Operations:
   With only one employee, consider strategic hiring or partnerships to expand capacity if demand grows, ensuring operational scalability.

4. Prepare for Next Filing Deadlines:
   Maintain timely accounts and confirmation statement filings to avoid penalties and maintain good standing.

5. Financial Forecasting:
   Develop simple cash flow forecasts to anticipate funding needs and ensure sustainable growth without liquidity crunch.

---

Medical Analogy Summary

STONEPHARMA LIMITED’s financial "vital signs" — liquidity and equity — resemble a young patient with a robust heartbeat and improving strength. There are no symptoms of financial distress such as overdue obligations or declining reserves, suggesting the company is in good health for its age. With continued prudent management, the prognosis is positive, envisioning a healthy trajectory of growth and financial resilience.

---